Page 4 - Foralumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Foralumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Foralumab Today - Breaking & Trending Today

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel ....

United States , Irina Koffler , Hana Malik , Gabriele Cerrone , Tiziana Life Sciences , Lifesci Advisors , Tiziana Life Sciences Ltd , Patient Population Expanded Access Program , Business Development , Life Sciences , Secondary Progressive Multiple Sclerosis , Executive Chairman , Chief Executive Officer , Investor Relations , Sci Advisors ,

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel ....

United States , Irina Koffler , Hana Malik , Gabriele Cerrone , Tanuja Chitnis , Tiziana Life Sciences , Lifesci Advisors , Tiziana Life Sciences Ltd , Patient Population Expanded Access Program , Ann Romney Center , Business Development , Life Sciences , Secondary Progressive Multiple Sclerosis , Executive Chairman , Chief Executive Officer , Neurologic Diseases , Scientific Advisory Board , Investor Relations , Sci Advisors ,

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab

The second Expanded Access patient (EA2) demonstrated improved walking as measured by gait stability and enduranceThe patient showed clinically significant improvement in the Expanded Disability Status ....

Irina Koffler , Hana Malik , Howardl Weiner , Gabriele Cerrone , Tanuja Chitnis , Tiziana Life Sciences , Lifesci Advisors , Tiziana Life Sciences Ltd , Ann Romney Center , Business Development , Expanded Access , Expanded Disability Status Scale , Life Sciences , Executive Chairman , Chief Executive Officer , Neurologic Diseases , Scientific Advisory Board , Investor Relations , Sci Advisors ,

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following three months of treatment. ....

United States , Kunwar Shailubhai , Irina Koffler , Hana Malik , Howard Weiner , Tanuja Chitnis , Tarun Singhal , Lifesci Advisors , Drug Administration , Tiziana Life Sciences , Imaging Program In Neurologic Diseases , Professor Of Neurology At Harvard Medical School , Tiziana Life Sciences Nasdaq , Tiziana Life Sciences Ltd , Business Development , Access Program , Sclerosis Program , Positron Emission Tomography , Foot Walk , Intermediate Size Expanded Access , Life Sciences , Secondary Progressive Multiple Sclerosis , Chief Executive Officer , Chief Scientific Officer , Multiple Sclerosis Program , Scientific Advisory Board ,

Tiziana Life Sciences Ltd.: Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting

NEW YORK, June 01, 2022) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced that Dr. Tanuja Chitnis ....

United States , Irina Koffler , Hana Malik , Tanuja Chitnis , Lifesci Advisors , Veterans Administration Ms Programs , Harvard Medical School , Consortium Of Multiple Sclerosis Centersby Tiziana On , Tiziana Life Sciences , Tiziana Life Sciences Ltd , Gems Centers , Business Development , Multiple Sclerosis , Multiple Sclerosis Centersby Tiziana , Blood Inflammatory Biomarkers , Non Active Secondary Progressive , Harvard Medical , Life Sciences , Investor Relations , Sci Advisors ,